Abstract Library

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4132 ACTION-1: A randomised phase Ib/3 trial of RYZ101 compared with standard of care in somatostatin receptor positive, well-differentiated gastroenteropancreatic neuroendocrine tumors with progression following 177Lu somatostatin analogue therapy

Introduction: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are characterized by high-density expression of somatostatin receptors (SSTRs). RYZ101 (225Ac-DOTATATE) is a highly potent alpha-emitting radiopharmaceutical therapy (RPT) being developed for SSTR+ solid tumors. ACTION-1 is a 2-part, global, randomized, controlled, open-label, Phase 1b/3 trial of RYZ101. Part 1 (Phase 1b), an uncontrolled dose de-escalation study, is complete with no dose-limiting toxicities.

Conference:

Presenting Author: Singh S

Authors: Singh S, Tesselaar M, Strosberg J, Jacene H, Halperin D,

Keywords: RYZ101, Gastroenteropancreatic neuroendocrine tumor, Somatostatin receptor, Radiopharmaceutical therapy,

#3273 LIBRETTO-531: Selpercatinib vs standard of care in patients (pts) with multikinase inhibitor-naïve advanced or metastatic RET-mutant (mut) medullary thyroid cancer (MTC)

Introduction: Multikinase inhibitors (MKI) are approved for MTC; however, their efficacy in RETmut MTC is limited due to incomplete RET inhibition and significant toxicity. Selpercatinib (LOXO-292), a highly selective and potent FDA approved inhibitor of RET alterations including M918T, MKI resistance-associated V804M, and others, showed robust, durable clinical activity with a tolerable profile in pts with RETmut MTC in the Phase 1/2 LIBRETTO-001 study.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Leboulleux S, Robinson B, Hoff A, Brose M, Wirth L,

Keywords: RET alteration, medullary thyroid cancer (MTC), phase 3 trial, selpercatinib,

#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging

Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Antwi K

Authors: Antwi K, Hepprich M, Reubi J, Christ E, Wild D,

Keywords: insulinoma, GLP-1R imaging,

#2003 Comparison of Glucagon-Like-Peptide-1 (GLP-1) Receptor PET/CT, SPECT/CT and 3T MRI for the Localisation of Insulinomas: Evaluation of Accuracy in a Prospective Crossover Imaging Study

Introduction: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults and due to their small size difficult to localise.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Antwi A, Heye T, Fani M, Nicolas G, Merkle E,

Keywords: Insulinoma, neuroendocrine tumor, GLP-1R imaging,